[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D001682:Biological Availability; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004164:Diphosphonates / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D051228:Geranyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D015337:Multicenter Studies as Topic; D010001:Osteitis Deformans / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010349:Patient Compliance; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D011795:Surveys and Questionnaires; D013997:Time Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D010919:Placebos; D000077211:Zoledronic Acid; D051228:Geranyltranstransferase; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate